Outset Medical, Inc. — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
Outset Medical reported Q3 2026 revenue of $33.6M (up 14% YoY from $29.4M), with console revenue $10.5M (+26% YoY) and recurring revenue $23.1M (+10% YoY). Gross margin expanded 130 bps to 40.7% vs 39.4% YoY. Net loss was $14.7M vs $17.8M in Q3 2025. Cash position declined to $140.7M (including restricted cash and investments) from $182.0M YoY due to $32.9M operating cash burn in nine months. Company reaffirmed FY2026 guidance of $125–$130M revenue and low-40% to mid-40% non-GAAP gross margin.
Why this rating
Modest revenue growth and margin improvement offset by ongoing cash burn and net losses. Company remains pre-breakeven; $140.7M cash supports ~18–24 months runway at current burn rate. Improving unit economics and gross margins show progress, but scale insufficient relative to $334.7M market cap to be transformational.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.